The paper retrieves the orphan drug data from European Medicines Agency (EMA) database. The detailed analysis on orphan drugs is from aspects as publishing years, drug categories, active ingredients, company distribution and so on, then how legislation on orphan drugs would affect new drug development is discussed, so as to provide references for our country in the rare disease and orphan drug management.